循環腫瘤細胞 (CTC) 和液體活檢相關研究
CTC臨床研究
CTC與其他技術的比較
CTC和液體活檢
Q-REstrain
RGCC 能提供什麼？
Oncotrace
Oncotrace 是癌症治療方案管理和追蹤的重要一步。它透過研究癌症幹細胞 (CSC) 標記物，為我們提供了目前 CTC 計數的資訊以及這些細胞的侵襲性概況。透過在分子層面上研究癌症行為，醫生和患者可以監測與遷移、增殖、抗藥性和轉移相關的腫瘤標記的活性。
Onconomics
Onconomics 是選擇個人化治療方案的一站式解決方案。 Onconomics Plus 可以向您展示特定抗癌藥物和標靶療法對單一癌細胞的療效。它全面分析了最合適、最有效的癌症治療方法。
Immune frame
免疫框架透過全面評估人體免疫系統的優勢和劣勢，深入了解人體目前的免疫系統狀態。這項綜合評估對於癌症存活至關重要，並有助於選擇各種精準的免疫治療方案。
ChemoSNiP
當藥物被注入人體時，人體會對藥物本身做出反應。並非所有患者對化療的反應都相同。 ChemoSNIP 可以觀察人體對化療藥物的反應。這可以告訴我們人體是否會快速清除藥物，進而降低其療效；或排毒能力較差，進而增加中毒風險。 ChemoSNIP 讓所有臨床醫生分析患者身體對特定藥物的反應。
與 Sarah 博士交談
在RGCC，我們致力於為像您這樣的從業人員提供持續的支援。我們誠摯地邀請您與我們的醫學顧問Sarah Khong醫生進行一對一諮詢，以幫助您更了解並使用我們的服務。 
Dr. Sarah Khong
醫師發展與網絡管理總監
Clinical study of CTC
No. | Name of Research | Year | Summary |
1 | Adjusting Treatment Strategies Using Circulating Tumor Cells | 2024 | A clinical study showed that using CTC-based chemosensitivity assays in metastatic colorectal cancer can guide second-line treatments, significantly improving median overall survival from 5 to 9 months. This method tailors therapy based on CTC response, enhancing patient outcomes over best supportive care. |
2 | Correlation of CTCs with Cancer Stage | 2024 | A study of over 14,000 cancer patients found a strong linear correlation (R² = 0.995) between CTC count and cancer stage. CTCs were shown to increase with disease progression, highlighting their value as biomarkers for staging, prognosis, and treatment monitoring. |
3 | Flow Cytometric Detection of CTCs in Breast Cancer | 2019 | A blinded study validated a flow cytometric panel for detecting CTCs in breast cancer, achieving 90.16% sensitivity and 77.42% specificity. It demonstrated high diagnostic potential using a non-invasive, reproducible technique. |
4 | CTCs and Outcomes in Colorectal Cancer | 2022 | A study of 48 CRC patients found that post-treatment CTC and MCTC counts strongly correlate with shorter progression-free and overall survival. More than 6 CTCs or 5 MCTCs/5mL blood indicated poor prognosis, confirming CTCs as critical biomarkers. |
No. | Name of Research | Year | Summary |
1 | Circulating Tumor Cells Versus Circulating Tumor DNA in Colorectal Cancer: Pros and Cons | 2016 | This review highlights the complementary roles of CTCs and ctDNA in colorectal cancer, discussing their utility in diagnosis, prognosis, and treatment monitoring. CTCs provide phenotypic insights and can guide drug resistance analysis, while ctDNA offers mutation tracking with high sensitivity. Each has unique strengths depending on the clinical context. |
2 | Liquid Biopsy: Comprehensive Overview of Circulating Tumor DNA | 2024 | This review presents a detailed evaluation of ctDNA, covering its biology, detection technologies, and clinical relevance. It emphasizes ctDNA’s non-invasive nature, prognostic utility, and role in monitoring therapeutic response, but notes current challenges in sensitivity, cost, and standardization. |
3 | Circulating Tumor Cells Versus Circulating Tumor DNA in Lung Cancer | 2016 | This paper compares CTCs and ctDNA as liquid biopsy tools in lung cancer. While ctDNA is easier to collect and analyze, CTCs offer richer phenotypic and genotypic data. The study emphasizes the need for standardization and highlights both biomarkers’ roles in diagnosis, treatment monitoring, and resistance profiling. |
Comparison of CTC to other technologies
CTC and Liquid Biopsy
No. | Name of Research | Year | Summary |
1 | Advancements in Circulating Tumor Cell Research: Bridging Biology and Clinical Applications | 2024 | This review highlights recent progress in CTC detection, their role in early cancer detection, prognosis, monitoring treatment response, and understanding tumor heterogeneity. It also discusses current challenges and emerging technologies for CTC isolation and analysis in clinical practice. |
2 | Clinical Utility of Circulating Tumor Cells: An Update | 2020 | Summarizes the prognostic significance of CTCs across cancer types and stages, especially breast, colorectal, prostate, and lung cancers. Discusses their potential role in treatment decisions, clinical trials, and molecular characterization for personalized therapy. |
3 | The Contribution of Liquid Biopsy in Diagnosis and Prognosis of Colorectal Cancer | 2021 | Reviews the utility of liquid biopsy in CRC, focusing on CTCs, ctDNA, and exosomes. Highlights their roles in early detection, prognosis, treatment monitoring, and personalized therapy. Emphasizes the potential of CTC count as an indicator of disease progression and treatment response. |
4 | Detection of Circulating Tumor Cells: Opportunities and Challenges | 2022 | This article details CTC biology and outlines various detection techniques including label-dependent and independent methods. It discusses opportunities for CTC use in precision oncology and addresses limitations such as rarity, heterogeneity, and technical challenges. |
5 | Circulating Tumor Cells in the Early Detection of Human Cancers | 2022 | Explores the biology and role of CTCs in cancer metastasis and early detection. Reviews isolation technologies and their application across cancer types, emphasizing the potential of CTCs in improving early diagnosis, monitoring recurrence, and tailoring treatments. |
No. | Name of Research | Year | Summary |
1 | Supportive Oligonucleotide Therapy (SOT) as an Alternative Treatment Option in Cancer | 2022 | This preliminary study assessed the effectiveness of SOT, an siRNA-based therapy targeting gene expression in cancer. Among 95 patients, SOT reduced CTC counts significantly in both monotherapy and adjunctive use. Clinical improvement and Karnofsky Index enhancement were observed in over 70% of patients, showing potential as a supportive cancer therapy. |
Q-REstrain
